GlassScriptPhysician profile
Regina Kogan
NPI 1851603575
$2,416.11
in general payments reported to CMS, 2019-2025
24 companies · $29.03 in 2025
The $29.03 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.27 · 2020: $102 · 2021: $499 · 2022: $691 · 2023: $636 · 2024: $447 · 2025: $29.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.93 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $375.44 | 2023-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $299.51 | 2022 | |
| Exeltis, USA INC. | $219.30 | 2021-2024 | Slynd |
| Abbvie INC. | $217.61 | 2021-2025 | |
| Myovant Sciences INC. | $197.13 | 2021-2022 | |
| Avion Pharmaceuticals | $187.92 | 2019-2023 | Balcoltra |
| Pfizer INC. | $146.81 | 2023-2024 | |
| Ascend Therapeutics US, LLC | $102.95 | 2023 | |
| Evofem Biosciences, INC. | $98.61 | 2021-2022 | |
| Shield Therapeutics INC | $81.48 | 2024 | |
| Sumitomo Pharma America, INC. | $81.40 | 2023-2024 | Myfembree |
| Aspira Women'S Health INC | $63.78 | 2022-2023 | Ova1 |
| Coopersurgical, INC. | $56.21 | 2021-2022 | |
| Agile Therapeutics, INC. | $43.06 | 2021-2023 | Twirla |
| Organon LLC | $40.57 | 2022-2024 | Nexplanon |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $38.26 | 2024 | Vumerity, Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $37.62 | 2022 | |
| Radius Health, INC. | $25.62 | 2024 | Tymlos |
| Mycovia Pharmaceuticals, INC. | $19.54 | 2023 | Vivjoa |
| Lilly USA, LLC | $18.22 | 2022 | |
| Scynexis, INC. | $18.16 | 2022 | |
| Duchesnay USA Incorporated | $16.50 | 2023 | Osphena, Bonjesta |
| Exact Sciences Corporation | $15.86 | 2023 | Cologuard Collection Kit |
| Mission Pharmacal Company | $14.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.